Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Clinical Trials

10 recruiting trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
1
Phase 3 Trials
7
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT07236762

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGEarly Phase 1NCT07246096

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of...

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cells in patients with autoimmune diseases. 60 patients are...

Sponsor: Changhai HospitalEnrolling: 601 location
RECRUITINGPhase 1NCT06978647

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 121 location
RECRUITINGPhase 1NCT07104721

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGPhase 1NCT07123519

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGPhase 1NCT06056921

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 241 location
RECRUITINGPhase 1 / Phase 2NCT06350110

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002...

Sponsor: Essen BiotechEnrolling: 751 location
RECRUITINGPhase 1NCT06316076

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

To evaluate the safety and efficacy of CD19-CAR-DNT cells in subjects with relapsed/refractory autoimmune diseases

Sponsor: RenJi HospitalEnrolling: 481 location
RECRUITINGPhase 3NCT04871191

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

The purpose of this study is to identify the most promising therapeutic strategy for patients with granulomatosis with polyangiitis and inadequate response to standard of care...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 421 location
RECRUITINGPhase 2NCT07160608

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated...

The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 7520 locations